Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

被引：167

作者：

Miller, Elizabeth ^{[1
]}

Andrews, Nicholas J. ^{[2
]}

Waight, Pauline A. ^{[1
]}

Slack, Mary P. E. ^{[3
]}

George, Robert C. ^{[3
]}

机构：

[1] Hlth Protect Agcy, Hlth Protect Serv, Immunisat Hepatitis & Blood Safety Dept, London NW9 5EQ, England

[2] Hlth Protect Agcy, Hlth Protect Serv, Stat Modelling & Econ Dept, London NW9 5EQ, England

[3] Hlth Protect Agcy, Microbiol Serv Div, Resp & System Infect Lab, London NW9 5EQ, England

来源：

VACCINE | 2011年 / 29卷 / 49期

关键词：

Pneumococcal conjugate vaccine; Vaccine effectiveness; 13-Valent vaccine; Invasive pneumococcal disease; EFFICACY; IMMUNOGENICITY; CHILDREN; DISEASE; TRIAL;

D O I：

10.1016/j.vaccine.2011.09.112

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Efficacy of the new serotypes in the 13-valent pneumococcal conjugate vaccine (PCV13) against invasive pneumococcal disease (IPD) was based on a putative correlate of protection. In England and Wales, PCV13 replaced PCV7 in the 2, 4, and 13 month schedule in April 2010. Using non-vaccine type IPD cases as controls, we estimated vaccine effectiveness (VE) for the new serotypes. Among 166 IPD cases in PCV13 eligible children reported by July 2011 with known serotype and vaccination status, VE for 2 doses under a year was 78% (95% confidence interval -18% to 96%) and 77% (38-91%) for one dose over a year. VE for 7F and 19A was 76% (21-93%) and 70% (10-90%) respectively for >= one dose. VE for serotypes 1 and 3 was 62% and 66% respectively although confidence intervals spanned zero. LPD due to PCV13-only serotypes halved in children under 2 years in the study period. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：9127 / 9131

页数：5

共 18 条

[1]

[Anonymous], 2010, Wkly Epidemiol Rec, V85, P434

[2] PNEUMOCOCCAL DISEASE AFTER PNEUMOCOCCAL VACCINATION - AN ALTERNATIVE METHOD TO ESTIMATE THE EFFICACY OF PNEUMOCOCCAL VACCINE [J].

BROOME, CV ;

FACKLAM, RR ;

FRASER, DW .

NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (10) :549-552

[3]

Cohen R, 2011, INT C ANT AG CHEM SE

[4] The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A [J].

Cooper, David ;

Yu, Xinhong ;

Sidhu, Mohinder ;

Nahm, Moon H. ;

Fernsten, Philip ;

Jansen, Kathrin U. .

VACCINE, 2011, 29 (41) :7207-7211

[5] Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial [J].

Cutts, FT ;

Zaman, SMA ;

Enwere, G ;

Jaffar, S ;

Levine, OS ;

Okoko, JB ;

Oluwalana, C ;

Vaughan, A ;

Obaro, SK ;

Leach, A ;

McAdam, KP ;

Biney, E ;

Saaka, M ;

Onwuchekwa, U ;

Yallop, F ;

Pierce, NF ;

Greenwood, BM ;

Adegbola, RA .

LANCET, 2005, 365 (9465) :1139-1146

[6] Effect of Pneumococcal Conjugate Vaccination on Serotype-Specific Carriage and Invasive Disease in England: A Cross-Sectional Study [J].

Flasche, Stefan ;

Van Hoek, Albert Jan ;

Sheasby, Elizabeth ;

Waight, Pauline ;

Andrews, Nick ;

Sheppard, Carmen ;

George, Robert ;

Miller, Elizabeth .

PLOS MEDICINE, 2011, 8 (04) :14

[7] Immunogenicity of a Reduced Schedule of Pneumococcal Conjugate Vaccine in Healthy Infants and Correlates of Protection for Serotype 6B in the United Kingdom [J].

Goldblatt, David ;

Southern, Jo ;

Ashton, Lindsey ;

Andrews, Nick ;

Woodgate, Sarah ;

Burbidge, Polly ;

Waight, Pauline ;

Miller, Elizabeth .

PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (05) :401-405

[8]

Grimprel E, 2009, 27 ANN M EUR SOC PAE

[9] Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? [J].

Hausdorff, William P. ;

Hoet, Bernard ;

Schuerman, Lode .

BMC PEDIATRICS, 2010, 10

[10]

HPA, 2011, HLTH PROT REP, V5

← 1 2 →